论文部分内容阅读
“聚肌胞(全称多聚次黄嘌呤核甙酸PolyI∶C)研究试制协作组”主办,邀请了部分用药单位和卫生药检部门的代表与协作组的同志们一起交流了聚肌胞试用的效果、经验和体会,讨论了干扰素及其诱导物聚肌胞治疗肝炎的临床机理和前途,并对选择病例、用药方法、剂量和指征等问题进行了研究。聚肌胞是个高效、广谱干扰素诱导剂,具有抗病毒、抗肿瘤、刺激免疫、抗某些细菌、原虫感染等多种作用。国际上自1957年发现干扰素,1967年研制成功聚肌胞以来,
“Polymyosin (Polyisocyanate PolyI: C) research trial collaboration group” hosted by the invited part of the drug unit and the health drug inspection department representatives and collaborative group comrades to discuss the poly-muscle trial Efficacy, experience and experience. The clinical mechanism and future of interferon and its induced poly polyarter to treat hepatitis were discussed. Some problems such as the selection of cases, methods of administration, dosage and indications were also studied. Polymyosin is an efficient, broad-spectrum interferon inducer with anti-viral, anti-tumor, immune stimuli, anti-bacterial and protozoal infections. Interferon has been found in the world since 1957. Since the successful development of polychaetes in 1967,